T‐cell stimulation and selectivity of antigen features are combined in one combination molecule.105 The initial group of CARs was examined in OC and other tumors inducing modest responses.105, 106 At the very first CAR T‐cells trial in OC, cancer load was not reduced in patients.106 FRα,107 HER‐2,108 CA125 (MUC16),109, 110 and mesothelin 111 are ensuring antigens for CARS. This evidence concerns the gene ERBB2 and cancer.